Allarity Therapeutics, Inc.
stenoparib
advanced ovarian cancer
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for stenoparib in advanced ovarian cancer are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“This study represents the first clinical evaluation of the stenoparib–temozolomide combination and expands the development potential of stenoparib beyond ovarian cancer into additional tumor types with significant unmet medical need.”